Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany.
Journal Information
Full Title: Acta Haematol
Abbreviation: Acta Haematol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of Interest Statement M. Reiser, K.M. Josten, and H. Dietzfelbinger have nothing to declare. A. Seesaghur, M. Schill, and J. Hippenmeyer are employees and shareholders of Amgen. M. Welslau reports advisory or expert activity for Amgen, Bristol Myers Squibb, Celgene, Gilead, Hexal, Janssen, Lilly, medac, Novartis, Roche, and Sanofi, and receipt of honoraria from Amgen, Astellas, AstraZeneca, Celgene, Gilead, Hexal, Janssen, Lilly, Novartis, Roche, and Sanofi."
"Funding Sources This study was funded by Amgen (Europe) GmbH. The study sponsor, Amgen (Europe) GmbH (München, Germany), played a role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025